Eli Lilly to target cancer drug developers for deals
(Reuters) - Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.
“Probably because of the number of opportunities, you will see us active in oncology - that’s where a lot of early stage biotech is,” Ricks said.
OCTOBER 23, 2019
https://www.reuters.com/